the Merger

Broadway Financial Corporation and CFBanc Corporation Complete Merger of Equals

Retrieved on: 
Thursday, April 1, 2021
Banking, Professional services, Finance, Banks of the United States, Keefe, Bruyette & Woods, Companies, Finance, Broadway Federal Bank, Stifel, Fairness opinion, the Merger, CityFirstBroadway

Broadway Financial Corporation (Broadway") (Nasdaq-CM: BYFC) and CFBanc Corporation (CFB) jointly announced that they closed their merger of equals today.

Key Points: 
  • Broadway Financial Corporation (Broadway") (Nasdaq-CM: BYFC) and CFBanc Corporation (CFB) jointly announced that they closed their merger of equals today.
  • Under the terms of the merger agreement, CFB merged with and into Broadway, with Broadway being the surviving bank holding company.
  • Keefe, Bruyette & Woods, A Stifel Company, acted as financial advisor and rendered a fairness opinion to the board of directors of Broadway in connection with the merger.
  • Broadway Financial Corporation (Nasdaq-CM: BYFC), a bank holding company, and its wholly-owned bank subsidiary, City First Bank, National Association (the Bank), are collectively referred to as CityFirstBroadway.

Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease

Retrieved on: 
Tuesday, August 18, 2020
Research, Finance, Public relations, Investor relations, Clinical trials, Communications, Professional services, Biotechnology, General Health, Health, Science, Biotechnology, Chinook, the Merger, Chinook Therapeutics

The private placement closing is expected to occur immediately prior to the closing of the previously announced proposed merger between Chinook and Aduro Biotech, Inc. (NASDAQ: ADRO).

Key Points: 
  • The private placement closing is expected to occur immediately prior to the closing of the previously announced proposed merger between Chinook and Aduro Biotech, Inc. (NASDAQ: ADRO).
  • Closing of the private placement is subject to the satisfaction or waiver of all closing conditions for the proposed merger.
  • Following the private placement financing, and upon closing of the merger, Chinook is expected to have at least $275 million in operating capital.
  • Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases.